…3-50.7); PFS=12.8 months (95% CI 6.6-18.8); ORR=not available]. Buparlisib plus fulvestrant presented the next best numerical efficacy [OS…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 197 of 2459…rence to oral antineoplastic therapy in patients diagnosed with chronic lymphocytic leukaemia, chronic myeloid leukaemia, or multiple myeloma.Material and Me…
…rescribed medications included: vitamins and supplements (41%), proton pump inhibitors (31.8%), benzodiazepines and non-steroidal anti-inflammatory dr…
…and diagnostic services and were less likely to be dispensed an ACE inhibitor or mineralocorticoid receptor antagonist after adjusting for re…
… of 5th graders and 22% of 10–14-year-olds affected in Estonia. Myopia raises the risk of serious eye diseases such as myopic macular …
…kaemia (n=2), myelodysplastic syndrome (n=2), and others (n=4). Vedolizumab was used as third-line therapy in seven patients, fourth-line i…
… Higher vitamin D has consistently been associated with a lower multiple sclerosis (MS) risk, but some controversy remains about whether this is d…
… Hg; 95% CI (2.8 to 19.57)) were significantly increased during LI-BFR versus LI-RE, while HR was not significant (MD=6.00 bpm; 95% CI…
…%) in peripartum cardiomyopathy, 2% (2/102; 95% CI 0% to 7%) in Takotsubo syndrome and 1% (8/594; 95% CI 1% to 3%) for congenital/inherited or gen…
…).Conclusion We found no evidence for a better effectiveness of TNFi in patients with very early versus established axSpA.…
… Adverse events were almost exclusively in Arm 3, attributed to nivolumab. One patient achieved MRD (Arm 2), and three patients had an RC…
…oglobulin G and A levels were inversely associated with IMD. In SjD, each unit increase in IMD reduced IgG by 6.03% (−9.84%, −2.05%…